NRSN NeuroSense Therapeutics
- 1.260
- +0.050+4.13%
- 1.300
- +0.040+3.17%
NeuroSense Therapeutics News
F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
F-1: Registration statement for securities of certain foreign private issuers
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
